Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
875 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fallopian Tube Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2017, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape. Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 59, 37, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 6 and 2 molecules, respectively. Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Fallopian Tube Cancer - Overview 7 Fallopian Tube Cancer - Therapeutics Development 8 Fallopian Tube Cancer - Therapeutics Assessment 24 Fallopian Tube Cancer - Companies Involved in Therapeutics Development 40 Fallopian Tube Cancer - Drug Profiles 80 Fallopian Tube Cancer - Dormant Projects 846 Fallopian Tube Cancer - Discontinued Products 849 Fallopian Tube Cancer - Product Development Milestones 850 Appendix 860
List of Tables
Number of Products under Development for Fallopian Tube Cancer, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017 Fallopian Tube Cancer - Pipeline by Aduro BioTech Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 Fallopian Tube Cancer - Pipeline by Altor BioScience Corp, H2 2017 Fallopian Tube Cancer - Pipeline by Amgen Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017 Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017 Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2017 Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2017 Fallopian Tube Cancer - Pipeline by BeiGene Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Fallopian Tube Cancer - Pipeline by Boston Biomedical Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017 Fallopian Tube Cancer - Pipeline by Celgene Corp, H2 2017 Fallopian Tube Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Celsion Corp, H2 2017 Fallopian Tube Cancer - Pipeline by Celyad SA, H2 2017 Fallopian Tube Cancer - Pipeline by Clovis Oncology Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Eisai Co Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Eli Lilly and Co, H2 2017 Fallopian Tube Cancer - Pipeline by EpiThany Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Exelixis Inc, H2 2017 Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Galena Biopharma Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Genentech Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H2 2017 Fallopian Tube Cancer - Pipeline by Gradalis Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Ignyta Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Immune Design Corp, H2 2017 Fallopian Tube Cancer - Pipeline by ImmunoGen Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Immunovaccine Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Innate Pharma SA, H2 2017 Fallopian Tube Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2017 Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Mabion SA, H2 2017 Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 Fallopian Tube Cancer - Pipeline by MedImmune LLC, H2 2017 Fallopian Tube Cancer - Pipeline by Medivir AB, H2 2017 Fallopian Tube Cancer - Pipeline by Merck & Co Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Merck KGaA, H2 2017 Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 Fallopian Tube Cancer - Pipeline by MolMed SpA, H2 2017 Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc, H2 2017 Fallopian Tube Cancer - Pipeline by NewLink Genetics Corp, H2 2017 Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2017 Fallopian Tube Cancer - Pipeline by Novogen Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2017 Fallopian Tube Cancer - Pipeline by OBI Pharma Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Oncobiologics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Oncolix Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc, H2 2017 Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H2 2017 Fallopian Tube Cancer - Pipeline by Pfizer Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Pharma Mar SA, H2 2017 Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by PTC Therapeutics Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017 Fallopian Tube Cancer - Pipeline by Rigel Pharmaceuticals Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Samyang Holdings Corp, H2 2017 Fallopian Tube Cancer - Pipeline by Sanofi, H2 2017 Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2017 Fallopian Tube Cancer - Pipeline by Sotio AS, H2 2017 Fallopian Tube Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2017 Fallopian Tube Cancer - Pipeline by TapImmune Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Tesaro Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Tyrogenex Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd, H2 2017 Fallopian Tube Cancer - Pipeline by Verastem Inc, H2 2017 Fallopian Tube Cancer - Pipeline by Vyriad Inc, H2 2017 Fallopian Tube Cancer - Dormant Projects, H2 2017 Fallopian Tube Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 Fallopian Tube Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 Fallopian Tube Cancer - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
